All In Biotech

Drug Trial Radar · NCT06118281

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Jun 25, 2024

Primary completion

Jan 29, 2027

Study completion Jan 29, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
Collaborators
Duke Clinical Research Institute
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

Conditions

  • Cardiovascular Risk
  • Acute Myocardial Infarction (AMI)

Interventions

  • ZiltivekimabDrug

    Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.

  • PlaceboDrug

    Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal strokeTime frame: From randomisation (month 0) to end-of-study (up to 25 months)

Locations

836 sites in 24 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular, LLC

    Alexander City, Alabama

  • Birmingham VA Medical Center

    Birmingham, Alabama

  • Grandview Medical Center

    Birmingham, Alabama

  • Eastern Shore Rsrch Inst, LLC

    Fairhope, Alabama

  • Heart Center Rsrch_Hunstville

    Huntsville, Alabama

  • Mobile Heart USA Health Cardiology Clinic

    Mobile, Alabama

  • Mercy Gilbert Medical Center

    Gilbert, Arizona

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Honor Health

    Scottsdale, Arizona

  • Arkansas Cardiology Clinic

    Little Rock, Arkansas

  • Central Arkansas Veteran's Healthcare System

    Little Rock, Arkansas

  • Valley Clinical Trials

    Covina, California

  • UCSD Medical Center

    La Jolla, California

  • Loma Linda University Faculty Medical Clinics

    Loma Linda, California

  • VAGrtrLosAngelesHlthcareSystem

    Los Angeles, California

  • University of Californ LA-UCLA

    Los Angeles, California

  • University Of California Irvine

    Orange, California

  • Kaiser Permanente Viewridge Medical Offices

    San Diego, California

  • San Diego Cardiac Center

    San Diego, California

  • San Francisco V.A. Medical Center

    San Francisco, California

  • LA BioMed Harbor UCLA Med Cenr

    Torrance, California

  • Torrance Memorial Medical Center

    Torrance, California

  • Interventional Cardiology Medical Group

    West Hills, California

  • University of CO - Division of Cardiology

    Aurora, Colorado

  • Denver Health Medical Center

    Denver, Colorado

  • Colorado Heart and Vascular PC

    Golden, Colorado

  • S Denver Cardiology Associates

    Littleton, Colorado

  • Advanced Heart & Vein Center

    Thornton, Colorado

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • Danbury Hospital - Cardiology Department

    Danbury, Connecticut

  • Yale Ctr for Clin Invest

    New Haven, Connecticut

  • Cardiology Associates of Fairfield County

    Stamford, Connecticut

  • Christiana Care Health Services, Inc.

    Newark, Delaware

  • MedStar Hlth Res Institute

    Washington D.C., District of Columbia

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • University of Florida

    Gainesville, Florida

  • Memorial Healthcare

    Hollywood, Florida

  • UF Hlth Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Baptist Heart Specialists

    Jacksonville, Florida

Showing 40 of 836 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.